Literature DB >> 6206238

Indiscriminate degradation of RNAs in interferon-treated, vaccinia virus-infected mouse L cells.

J Benavente, E Paez, M Esteban.   

Abstract

In this report we used Northern blot hybridization analysis to characterize the fate of several species of viral RNA transcribed from internal and terminal regions of vaccinia DNA in interferon-treated, infected mouse L cells grown in suspension. All species of viral RNAs were expressed but were reduced in amount. Larger-sized RNAs were reduced more than smaller-sized RNAs. This reduction appears to be related to the activation of the interferon-mediated double-stranded RNA-dependent 2-5A synthetase-endoribonuclease system, as the rRNA cleavage pattern characteristic of this system was observed early in infection and in cell extracts in response to exogenous 2-5A. Thus, in interferon-treated, vaccinia-infected mouse L cells in suspension, there is indiscriminate degradation of viral and cellular RNAs, and this RNA breakdown might play a role in the interferon-mediated inhibition of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206238      PMCID: PMC255857     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis.

Authors:  W K Roberts; A Hovanessian; R E Brown; M J Clemens; I M Kerr
Journal:  Nature       Date:  1976-12-02       Impact factor: 49.962

2.  Interferon, double-stranded RNA, and protein phosphorylation.

Authors:  B Lebleu; G C Sen; S Shaila; B Cabrer; P Lengyel
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

3.  Specific phosphorylation in vitro of a protein associated with ribosomes of interferon-treated mouse L cells.

Authors:  A Zilberstein; P Federman; L Shulman; M Revel
Journal:  FEBS Lett       Date:  1976-09-15       Impact factor: 4.124

4.  Interferon action may be mediated by activation of a nuclease by pppA2'p5'A2'p5'A.

Authors:  C Baglioni; M A Minks; P A Maroney
Journal:  Nature       Date:  1978-06-22       Impact factor: 49.962

5.  Interferon, double-stranded RNA and RNA degradation. Characteristics of an endonuclease activity.

Authors:  L Ratner; G C Sen; G E Brown; B Lebleu; M Kawakita; B Cabrer; E Slattery; P Lengyel
Journal:  Eur J Biochem       Date:  1977-10-03

6.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

7.  pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.

Authors:  I M Kerr; R E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

8.  Early virus protein synthesis in vaccinia virus-infected cells.

Authors:  M Esteban; D H Metz
Journal:  J Gen Virol       Date:  1973-05       Impact factor: 3.891

9.  Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis.

Authors:  P J Farrell; K Balkow; T Hunt; R J Jackson; H Trachsel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

10.  Effect of interferon on integrity of vaccinia virus and ribosomal RNA in infected cells.

Authors:  M Esteban; J Benavente; E Paez
Journal:  Virology       Date:  1984-04-15       Impact factor: 3.616

View more
  3 in total

1.  Modulation of ppp(A2'p)nA-dependent RNase by a temperature-sensitive mutant of vaccinia virus.

Authors:  R J Cohrs; R C Condit; R F Pacha; C L Thompson; O K Sharma
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Novel 2',5'-oligoadenylates synthesized in interferon-treated, vaccinia virus-infected cells.

Authors:  A P Rice; S M Kerr; W K Roberts; R E Brown; I M Kerr
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

Review 3.  Poxvirus pathogenesis.

Authors:  R M Buller; G J Palumbo
Journal:  Microbiol Rev       Date:  1991-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.